 SOUTH SAN FRANCISCO, Calif., June 23, 2021 GLOBE NEWSWIRE -- Cytokinetics, Incorporated Nasdaq:CYTK today announced three presentations at Heart Failure 2021, an International Congress of the European Society of Cardiology taking place online from June 29, 2021 July 1, 2021. The presentations will include a Late Breaking Clinical Trial Session with additional analyses from GALACTIC-HF Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure relating to the influence of baseline atrial fibrillation on the treatment effect of omecamtiv mecarbil. Additional presentations will include secondary analyses from GALACTIC-HF relating to the effects of treatment with omecamtiv mecarbil on subgroups of patients in the trial. 